Pharmacological and cellular therapies to prevent restenosis after percutaneous transluminal angioplasty and stenting.
Angioplasty and stenting have become routine practice for the treatment of significant obstructive atherosclerotic vascular disease. This method of revascularization has a longer history concerning coronary artery disease but is becoming an increasingly used modality of revascularization in the peripheral circulation. Neointimal formation is the pathological basis for restenosis after revascularization procedures such as angioplasty, stenting, and bypass grafting. While restenosis is less of a problem in the coronary circulation with the advent of drug-eluting stents, it continues to be a problem however in the peripheral arterial system. Current treatments to prevent restenosis include pharmacologic, mechanical and cellular approaches which we will discuss in this manuscript.
Kiernan
Thomas J
TJ
Cardiology Division, Section of Vascular Medicine and Cardiology Intervention, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, GRB-800, Boston, MA 02114, USA. tjkiernan@partners.org
Yan
Bryan P
BP
Cruz-Gonzalez
Ignacio
I
Cubeddu
Roberto J
RJ
Caldera
Angel
A
Kiernan
Gareth D
GD
Gupta
Vishal
V
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000818:Animals; D050197:Atherosclerosis / Q000628:therapy*; D003324:Coronary Artery Disease / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D033581:Stem Cell Transplantation; D015607:Stents / Q000009:adverse effects